JP2019517538A - 哺乳動物種における胚−胎仔移行を検出およびモジュレートするための改良された方法 - Google Patents

哺乳動物種における胚−胎仔移行を検出およびモジュレートするための改良された方法 Download PDF

Info

Publication number
JP2019517538A
JP2019517538A JP2018563796A JP2018563796A JP2019517538A JP 2019517538 A JP2019517538 A JP 2019517538A JP 2018563796 A JP2018563796 A JP 2018563796A JP 2018563796 A JP2018563796 A JP 2018563796A JP 2019517538 A JP2019517538 A JP 2019517538A
Authority
JP
Japan
Prior art keywords
cells
itr
expression
gene
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018563796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517538A5 (enExample
Inventor
ディー． ウェスト，マイケル
ディー． ウェスト，マイケル
ラロッカ，ダナ
Original Assignee
バイオタイム，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオタイム，インコーポレーテッド filed Critical バイオタイム，インコーポレーテッド
Publication of JP2019517538A publication Critical patent/JP2019517538A/ja
Priority to JP2022173706A priority Critical patent/JP2023017861A/ja
Publication of JP2019517538A5 publication Critical patent/JP2019517538A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
JP2018563796A 2016-06-07 2017-06-07 哺乳動物種における胚−胎仔移行を検出およびモジュレートするための改良された方法 Pending JP2019517538A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022173706A JP2023017861A (ja) 2016-06-07 2022-10-28 哺乳動物種における胚－胎仔移行を検出およびモジュレートするための改良された方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662347075P 2016-06-07 2016-06-07
US62/347,075 2016-06-07
US201762442219P 2017-01-04 2017-01-04
US62/442,219 2017-01-04
PCT/US2017/036452 WO2017214342A1 (en) 2016-06-07 2017-06-07 Improved methods for detecting and modulating the embryonic-fetal transition in mammalian species

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022173706A Division JP2023017861A (ja) 2016-06-07 2022-10-28 哺乳動物種における胚－胎仔移行を検出およびモジュレートするための改良された方法

Publications (2)

Publication Number Publication Date
JP2019517538A true JP2019517538A (ja) 2019-06-24
JP2019517538A5 JP2019517538A5 (enExample) 2025-08-08

Family

ID=60578097

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018563796A Pending JP2019517538A (ja) 2016-06-07 2017-06-07 哺乳動物種における胚−胎仔移行を検出およびモジュレートするための改良された方法
JP2022173706A Pending JP2023017861A (ja) 2016-06-07 2022-10-28 哺乳動物種における胚－胎仔移行を検出およびモジュレートするための改良された方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022173706A Pending JP2023017861A (ja) 2016-06-07 2022-10-28 哺乳動物種における胚－胎仔移行を検出およびモジュレートするための改良された方法

Country Status (6)

Country Link
US (4) US20190175691A1 (enExample)
EP (1) EP3463391A4 (enExample)
JP (2) JP2019517538A (enExample)
AU (2) AU2017278931B2 (enExample)
CA (1) CA3026874A1 (enExample)
WO (1) WO2017214342A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023017861A (ja) * 2016-06-07 2023-02-07 エージェックス セラピューティクス，インコーポレーテッド 哺乳動物種における胚－胎仔移行を検出およびモジュレートするための改良された方法
US12404493B2 (en) 2015-12-07 2025-09-02 Agex Therapeutics, Inc. Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells
US12421513B2 (en) 2013-06-05 2025-09-23 Reverse Bioengineering, Inc. Compositions and methods for induced tissue regeneration in mammalian species

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
CN108665091A (zh) * 2018-04-07 2018-10-16 深圳供电局有限公司 一种基于机器学习的物资智能调度方法
JP7419347B2 (ja) * 2018-04-23 2024-01-22 エイジェックス・セラピューティクス・インコーポレイテッド 哺乳動物細胞における組織再生の誘導及びセノリシスのための改良された方法
JP2022527507A (ja) * 2019-03-28 2022-06-02 エイジェックス・セラピューティクス・インコーポレイテッド 細胞外小胞を用いる組織再生の誘導
CA3151938A1 (en) * 2019-08-23 2021-03-04 Agex Therapeutics, Inc. Differentially-methylated regions of the genome useful as markers of embryo-adult transitions
EP4277637A4 (en) * 2021-01-12 2025-03-26 Reverse Bioengineering, Inc. METHODS FOR EX VIVO INDUCTION OF TISSUE REGENERATION IN MICROBIOPSY
EP4415742A4 (en) * 2021-10-15 2026-03-11 Reverse Bioengineering Inc METHODS FOR THE TEMPORAL REGULATION OF REPROGRAMMING FACTORS IN MAMMALIAN CELLS
WO2023114274A1 (en) * 2021-12-14 2023-06-22 Agex Therapeutics, Inc. Improved methods for inducing the maturation of mammalian cells
WO2025155773A1 (en) * 2024-01-19 2025-07-24 Gene Company (Pty)Ltd. Telomerase upregulating polynucleotide and method of use and treatment thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014197421A1 (en) * 2013-06-05 2014-12-11 Biotime, Inc. Compositions and methods for induced tissue regeneration in mammalian species
CN105435244A (zh) * 2015-12-02 2016-03-30 重庆高圣生物医药有限责任公司 Lin28a基因过表达腺相关病毒在促进创伤修复中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067245A2 (en) * 2007-11-20 2009-05-28 University Of Florida Research Foundation, Inc. Compositions and methods for tissue repair
US20130202564A1 (en) * 2010-04-09 2013-08-08 University Of Southern California Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration
AU2017278931B2 (en) * 2016-06-07 2023-06-29 Agex Therapeutics, Inc. Improved methods for detecting and modulating the embryonic-fetal transition in mammalian species

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014197421A1 (en) * 2013-06-05 2014-12-11 Biotime, Inc. Compositions and methods for induced tissue regeneration in mammalian species
CN105435244A (zh) * 2015-12-02 2016-03-30 重庆高圣生物医药有限责任公司 Lin28a基因过表达腺相关病毒在促进创伤修复中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CELL, vol. 155(4), JPN6021015789, 2013, pages 778 - 792, ISSN: 0004811852 *
THE INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, vol. 53, JPN6021015791, 2014, pages 343 - 351, ISSN: 0004562709 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12421513B2 (en) 2013-06-05 2025-09-23 Reverse Bioengineering, Inc. Compositions and methods for induced tissue regeneration in mammalian species
US12492400B2 (en) 2013-06-05 2025-12-09 Reverse Bioengineering, Inc. Compositions and methods for induced tissue regeneration in mammalian species
US12404493B2 (en) 2015-12-07 2025-09-02 Agex Therapeutics, Inc. Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells
JP2023017861A (ja) * 2016-06-07 2023-02-07 エージェックス セラピューティクス，インコーポレーテッド 哺乳動物種における胚－胎仔移行を検出およびモジュレートするための改良された方法

Also Published As

Publication number Publication date
EP3463391A4 (en) 2020-01-22
JP2023017861A (ja) 2023-02-07
US20220088138A1 (en) 2022-03-24
US20190175691A1 (en) 2019-06-13
CA3026874A1 (en) 2017-12-14
US20220160833A1 (en) 2022-05-26
US20220088137A1 (en) 2022-03-24
AU2023203808A1 (en) 2023-07-13
AU2017278931A1 (en) 2018-12-20
EP3463391A1 (en) 2019-04-10
WO2017214342A1 (en) 2017-12-14
AU2017278931B2 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
US20220088137A1 (en) Methods for detecting and modulating the embryonic-fetal transition in mammalian species
JP7419347B2 (ja) 哺乳動物細胞における組織再生の誘導及びセノリシスのための改良された方法
US12492400B2 (en) Compositions and methods for induced tissue regeneration in mammalian species
US20240066070A1 (en) Methods for the ex vivo induction of tissue regeneration in microbiopsies
US20240398987A1 (en) Methods for the temporal regulation of reprogramming factors in mammalian cells
US20240350553A1 (en) Methods for modulating the regenerative phenotype in mammalian cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210322

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221028

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221028

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221108

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221115

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221216

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250415

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250728